Modified Starch and Its Potentials as Excipient in Pharmaceutical formulations



Authored by Khalid Garba Mohammed

Despite its vast commercial value, native starch has some inherent weaknesses when it comes to pharmaceutical application, to mention few include; poor compressibility, low flow ability values and often drug/excipient compatibility problems. In this review, some potentials of modified starch with particular emphasis on their improved functionalities and applicability in pharmaceutical formulations were discussed. Basic requirements for pharmaceutical excipients and various modification methods for starch i.e chemical modification, physical and biotechnological methods were highlighted.Pharmaceutical applications of modified starches as tablet super disintegrant, sustained/controlled release polymer, plasma volume expanders and as directly compressible excipient in tablet formulations have been cited.





Comments

Post a Comment

Popular posts from this blog

Bioconjugation among Metallopharmaceuticals: A Review-Juniper Publishers

Image
  JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF DRUG DESIGNING & DEVELOPMENT Abstract This review pertains to an effort to notify the importance of metal binding of naturally occurring molecules. Metallopharmaceutical science is a huge discipline of multifarious applications. In due course of design of metallic drugs one has to rely upon biological relevance of the compound. Sometimes the target activity is lost into toxicity. Hence, the association of a biomolecule or modified bio-compound coordinated with metallic system is the essence of bioconjugation and is the need of hour. Bio-conjugated metallic complexes are always praised for better action. Some diseases have been exemplified in this review and a comprehensive way of presentation has been established throughout the text. Keywords: Bioconjugation; AD; Diabetes; Cancer; Antioxidant Introduction Bioconjugation is a met...
Read more

Bioactive Compound Produced from Actinomycetes- Streptomyces-Juniper Publishers

Image
  JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF DRUG DESIGNING & DEVELOPMENT Abstract The beginning of antibiotic-resistance among the bacteria is really unavoidable. Over the last 60 years, bacteria and, in particular, those pathogenic for humans have evolved toward anti-microbial drug resistance. For the treatment of infectious diseases antibiotics like penicillin and erythromycin are used but now these antibiotics become less effective because bacteria have become more resistant to such antibiotics. The development of new antimicrobial agents is an urgent medical need. Natural products are important sources of lead antimicrobial agents. Actinomycetes are soil dwelling and Gram positive bacteria and industrially wide range of bioactive secondary metabolites producers, including many antibiotics. More than75% of antibiotics are sourced from the genus Streptomyces. This review article focuses on microbial secondary metabolites from Streptomyces as new drugs to f...
Read more

Islet Cell Transplantation for Treating Type 1 Diabetes: The Bright Future of Drug Designing and Development-Juniper Publishers

Image
  JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF DRUG DESIGNING & DEVELOPMENT Short Communication The revolutionary process of islet transplantation for treating type 1 diabetes has been limited by the high level of graft failure. The process of islet isolation alone has been shown to negatively impact islet survival and function in vivo. In addition, insults mediated by the instant blood-mediated inflammatory reaction, hypoxia, ischemia and immune response significantly impact the islet allograft post transplantation [ 1 , 2 ]. Moreover, the immune response to alloantigens and recurrence of autoimmunity contribute to pancreatic islet transplant dysfunction [ 3 ]. Several approaches are being developed and tried to overcome this serious problem and novel drug designing is heavily involved with promising results and bright rewards. Some of these approaches are being discussed briefly in this commentary. Regenerating islet-derived protein 3 alpha; a pancreatic se...
Read more